Cohort profile: POPPY II – a population-based cohort examining the patterns and outcomes of prescription opioid use in New South Wales, Australia
Purpose The POPPY II cohort is an Australian state-based cohort linking data for a population of individuals prescribed opioid medicines, constructed to allow a robust examination of the long-term patterns and outcomes of prescription opioid use.Participants The cohort includes 3 569 433 adult New S...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2023-05-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/13/5/e068310.full |
_version_ | 1827213211574730752 |
---|---|
author | Natasa Gisev Sallie-Anne Pearson Timothy Dobbins David C Currow Fiona Blyth Sarah Larney Adrian Dunlop Richard P Mattick Andrew Wilson Louisa Degenhardt Thomas Murphy Luke Buizen |
author_facet | Natasa Gisev Sallie-Anne Pearson Timothy Dobbins David C Currow Fiona Blyth Sarah Larney Adrian Dunlop Richard P Mattick Andrew Wilson Louisa Degenhardt Thomas Murphy Luke Buizen |
author_sort | Natasa Gisev |
collection | DOAJ |
description | Purpose The POPPY II cohort is an Australian state-based cohort linking data for a population of individuals prescribed opioid medicines, constructed to allow a robust examination of the long-term patterns and outcomes of prescription opioid use.Participants The cohort includes 3 569 433 adult New South Wales residents who initiated a subsidised prescription opioid medicine between 2003 and 2018, identified through pharmacy dispensing data (Australian Pharmaceutical Benefits Scheme) and linked to 10 national and state datasets and registries including rich sociodemographic and medical services data.Findings to date Of the 3.57 million individuals included in the cohort, 52.7% were female and 1 in 4 people were aged ≥65 years at the time of cohort entry. Approximately 6% had evidence of cancer in the year prior to cohort entry. In the 3 months prior to cohort entry, 26.9% used a non-opioid analgesic and 20.5% used a psychotropic medicine. Overall, 1 in 5 individuals were initiated on a strong opioid (20.9%). The most commonly initiated opioid was paracetamol/codeine (61.3%), followed by oxycodone (16.3%).Future plans The POPPY II cohort will be updated periodically, both extending the follow-up duration of the existing cohort, and including new individuals initiating opioids. The POPPY II cohort will allow a range of aspects of opioid utilisation to be studied, including long-term trajectories of opioid use, development of a data-informed method to assess time-varying opioid exposure, and a range of outcomes including mortality, transition to opioid dependence, suicide and falls. The duration of the study period will allow examination of population-level impacts of changes to opioid monitoring and access, while the size of the cohort will also allow examination of important subpopulations such as people with cancer, musculoskeletal conditions or opioid use disorder. |
first_indexed | 2024-03-13T10:41:48Z |
format | Article |
id | doaj.art-327b0f8ca20b4806b46526ba53b92155 |
institution | Directory Open Access Journal |
issn | 2044-6055 |
language | English |
last_indexed | 2025-03-21T14:11:50Z |
publishDate | 2023-05-01 |
publisher | BMJ Publishing Group |
record_format | Article |
series | BMJ Open |
spelling | doaj.art-327b0f8ca20b4806b46526ba53b921552024-06-24T19:25:10ZengBMJ Publishing GroupBMJ Open2044-60552023-05-0113510.1136/bmjopen-2022-068310Cohort profile: POPPY II – a population-based cohort examining the patterns and outcomes of prescription opioid use in New South Wales, AustraliaNatasa Gisev0Sallie-Anne Pearson1Timothy Dobbins2David C Currow3Fiona Blyth4Sarah Larney5Adrian Dunlop6Richard P Mattick7Andrew Wilson8Louisa Degenhardt9Thomas Murphy10Luke Buizen11National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, New South Wales, AustraliaSchool of Population Health, University of New South Wales Medicine & Health, Sydney, New South Wales, AustraliaSchool of Population Health, University of New South Wales - Kensington Campus, Sydney, New South Wales, AustraliaFaculty of Science Medicine and Health, The University of Wollongong, Wollongong, New South Wales, Australia1 Sydney School of Public Health, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, AustraliaDepartment of Family Medicine and Emergency Medicine and Centre de Recherche du Centre Hospitalier, de l`Université de Montréal, Montreal, Quebec, CanadaSchool of Medicine and Public Health, The University of Newcastle, Newcastle, New South Wales, AustraliaNational Drug and Alcohol Research Centre, UNSW Sydney, Sydney, New South Wales, AustraliaMenzies Centre for Health Policy, The University of Sydney, Sydney, New South Wales, Australia6 National Drug and Alcohol Research Centre (NDARC), Faculty of Medicine, University of New South Wales, Sydney, New South Wales, AustraliaNational Drug and Alcohol Research Centre, UNSW Sydney, Sydney, New South Wales, AustraliaNational Drug and Alcohol Research Centre, UNSW Sydney, Sydney, New South Wales, AustraliaPurpose The POPPY II cohort is an Australian state-based cohort linking data for a population of individuals prescribed opioid medicines, constructed to allow a robust examination of the long-term patterns and outcomes of prescription opioid use.Participants The cohort includes 3 569 433 adult New South Wales residents who initiated a subsidised prescription opioid medicine between 2003 and 2018, identified through pharmacy dispensing data (Australian Pharmaceutical Benefits Scheme) and linked to 10 national and state datasets and registries including rich sociodemographic and medical services data.Findings to date Of the 3.57 million individuals included in the cohort, 52.7% were female and 1 in 4 people were aged ≥65 years at the time of cohort entry. Approximately 6% had evidence of cancer in the year prior to cohort entry. In the 3 months prior to cohort entry, 26.9% used a non-opioid analgesic and 20.5% used a psychotropic medicine. Overall, 1 in 5 individuals were initiated on a strong opioid (20.9%). The most commonly initiated opioid was paracetamol/codeine (61.3%), followed by oxycodone (16.3%).Future plans The POPPY II cohort will be updated periodically, both extending the follow-up duration of the existing cohort, and including new individuals initiating opioids. The POPPY II cohort will allow a range of aspects of opioid utilisation to be studied, including long-term trajectories of opioid use, development of a data-informed method to assess time-varying opioid exposure, and a range of outcomes including mortality, transition to opioid dependence, suicide and falls. The duration of the study period will allow examination of population-level impacts of changes to opioid monitoring and access, while the size of the cohort will also allow examination of important subpopulations such as people with cancer, musculoskeletal conditions or opioid use disorder.https://bmjopen.bmj.com/content/13/5/e068310.full |
spellingShingle | Natasa Gisev Sallie-Anne Pearson Timothy Dobbins David C Currow Fiona Blyth Sarah Larney Adrian Dunlop Richard P Mattick Andrew Wilson Louisa Degenhardt Thomas Murphy Luke Buizen Cohort profile: POPPY II – a population-based cohort examining the patterns and outcomes of prescription opioid use in New South Wales, Australia BMJ Open |
title | Cohort profile: POPPY II – a population-based cohort examining the patterns and outcomes of prescription opioid use in New South Wales, Australia |
title_full | Cohort profile: POPPY II – a population-based cohort examining the patterns and outcomes of prescription opioid use in New South Wales, Australia |
title_fullStr | Cohort profile: POPPY II – a population-based cohort examining the patterns and outcomes of prescription opioid use in New South Wales, Australia |
title_full_unstemmed | Cohort profile: POPPY II – a population-based cohort examining the patterns and outcomes of prescription opioid use in New South Wales, Australia |
title_short | Cohort profile: POPPY II – a population-based cohort examining the patterns and outcomes of prescription opioid use in New South Wales, Australia |
title_sort | cohort profile poppy ii a population based cohort examining the patterns and outcomes of prescription opioid use in new south wales australia |
url | https://bmjopen.bmj.com/content/13/5/e068310.full |
work_keys_str_mv | AT natasagisev cohortprofilepoppyiiapopulationbasedcohortexaminingthepatternsandoutcomesofprescriptionopioiduseinnewsouthwalesaustralia AT sallieannepearson cohortprofilepoppyiiapopulationbasedcohortexaminingthepatternsandoutcomesofprescriptionopioiduseinnewsouthwalesaustralia AT timothydobbins cohortprofilepoppyiiapopulationbasedcohortexaminingthepatternsandoutcomesofprescriptionopioiduseinnewsouthwalesaustralia AT davidccurrow cohortprofilepoppyiiapopulationbasedcohortexaminingthepatternsandoutcomesofprescriptionopioiduseinnewsouthwalesaustralia AT fionablyth cohortprofilepoppyiiapopulationbasedcohortexaminingthepatternsandoutcomesofprescriptionopioiduseinnewsouthwalesaustralia AT sarahlarney cohortprofilepoppyiiapopulationbasedcohortexaminingthepatternsandoutcomesofprescriptionopioiduseinnewsouthwalesaustralia AT adriandunlop cohortprofilepoppyiiapopulationbasedcohortexaminingthepatternsandoutcomesofprescriptionopioiduseinnewsouthwalesaustralia AT richardpmattick cohortprofilepoppyiiapopulationbasedcohortexaminingthepatternsandoutcomesofprescriptionopioiduseinnewsouthwalesaustralia AT andrewwilson cohortprofilepoppyiiapopulationbasedcohortexaminingthepatternsandoutcomesofprescriptionopioiduseinnewsouthwalesaustralia AT louisadegenhardt cohortprofilepoppyiiapopulationbasedcohortexaminingthepatternsandoutcomesofprescriptionopioiduseinnewsouthwalesaustralia AT thomasmurphy cohortprofilepoppyiiapopulationbasedcohortexaminingthepatternsandoutcomesofprescriptionopioiduseinnewsouthwalesaustralia AT lukebuizen cohortprofilepoppyiiapopulationbasedcohortexaminingthepatternsandoutcomesofprescriptionopioiduseinnewsouthwalesaustralia |